Key result
Exogenous administration of apelin-13 did not attenuate tubular injury but significantly impaired tubular cell proliferation following renal ischemia/reperfusion in mice.
Why the study?
Although apelin-13 has been reported to reduce kidney injury, its effects on tubular injury and sodium proximal transport in ischemia-induced acute kidney injury remain unclear.
Does apelin-13 improve renal function and reduce tubular injury in a murine model of ischemia/reperfusion-induced acute kidney injury?
Does apelin-13 improve renal function and reduce tubular injury in a murine model of ischemia/reperfusion-induced acute kidney injury?
Apelin-13 suppresses tubular proliferation and potentially impairs the adaptive response to renal ischemia/reperfusion injury in mice, suggesting it may not be beneficial for ischemia-induced AKI.
Answers are grounded in this paper and cite their sources.
Apelin-13 may impair tubular adaptation after renal I/R; leaves open effects on AKI recovery in clinical settings.
Introduction Acute kidney injury (AKI) is a clinical syndrome characterized by rapid decline in renal function with varying severity. In this context, tubular function is impaired in ischemia-induced AKI. Although there are no effective therapies for AKI, many compounds have been reported to reduce kidney injury, such as apelin-13. Considering the relevance of proximal tubular cells in maintaining fluid and electrolyte homeostasis, the effects of apelin-13 on tubular injury or sodium proximal transport remain unclear. Thus, the present study aims to evaluate the effects of exogenous administration of apelin-13 in the renal ischemia/reperfusion (I/R) model, with particular focus on renal function, injury markers, and tubular proliferation. Methods Male C57BL/6 mice were initially treated with a vehicle or high dose of apelin-13 (200 μg/kg/day) and subjected to kidney bilateral ischemia procedure for 30 min or a sham surgery. The mice were euthanized by exsanguination 2 d after the ischemic procedure. Then, the renal function was assessed through the plasma urea level and creatinine clearance. Tubular injury was evaluated by hematoxylin and eosin staining. Kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), megalin, Ki67, and phospho ERK 1/2 (Thr202/Tyr204) were evaluated through immunohistochemical or immunoblotting experiments. Moreover, the murine proximal tubular cells (TKPTS) were treated with apelin-13 (100 nM) to evaluate the activity of the Na + /H + exchanger isoform 3 (NHE3) via intracellular pH measurements. Results Initial administration of apelin-13 did not improve tubular injury, creatinine clearance, or plasma urea level after renal I/R. Moreover, KIM-1 and NGAL markers were markedly increased after renal I/R and were not reduced in the apelin-13 + I/R group. Furthermore, megalin downregulation by renal I/R was not prevented by apelin-13. Interestingly, apelin-13 worsened the renal responses to tubular proliferation after renal I/R as Ki67 and phosphorylation of ERK/1/2 (Thr202/Tyr204) were sharply reduced in the apelin-13 + I/R group. In vitro experiments also demonstrated that apelin-13 inhibited NHE3 activity in murine proximal tubular cells. Conclusion The overall findings suggest that apelin-13 suppresses tubular proliferation and potentially impairs the adaptive response to renal I/R injury, thereby highlighting its relevance in ischemia-induced AKI.
No takes yet. Share an insight, caveat, or question.
Gonçalves et al. (2025) studied Ischemia/reperfusion-induced acute kidney injury (n=27). Apelin-13 vs. Vehicle (1x PBS) was evaluated on Tubular cell proliferation (Ki67 staining, cells/field) (p=<0.0001). Exogenous administration of apelin-13 did not attenuate tubular injury but significantly impaired tubular cell proliferation following renal ischemia/reperfusion in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: